Financial PositionThe company has approximately $159.5 million in cash and equivalents and has made significant reductions in operating expenses, positioning it to streamline its platform for future steps.
Future OpportunitiesThe norovirus opportunity remains tangible, with the potential to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection, which results in significant global deaths annually.
Strategic DevelopmentThere is consideration of strategic alternatives and business development activities, including a focus on broader pipeline prospects.